Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL239045 | 0.80 | HSD11B1 (0.40) | HSD11B1 | |
| SCHEMBL14402875 | 0.74 | RAB9A (0.36) | KMT2AALDH1A1MEN1 | |
| SCHEMBL239090 | 0.68 | HSD11B1 (0.43) | KMT2AHSD11B1 | |
| SCHEMBL5689268 | 0.66 | NPC1 (0.43) | KMT2APKMMEN1 | |
| SCHEMBL3997556 | 0.65 | HSD11B1 (0.45) | CNR1CNR2HSD11B1 | |
| SCHEMBL16974727 | 0.65 | NOS1 (0.41) | — | |
| SCHEMBL1675682 | 0.63 | KMT2A (0.74) | CNR1CNR2KMT2AHSD11B1FAAH | |
| SCHEMBL241520 | 0.63 | OPRK1 (0.34) | — | |
| SCHEMBL14402861 | 0.62 | EPHX2 (0.37) | KMT2AALDH1A1MEN1 | |
| SCHEMBL240111 | 0.62 | RAB9A (0.41) | KMT2AHSD11B1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD3B1, HSD11B2 | CNR1 2847/4885CNR2 4088/4885KMT2A 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.